T-Therapeutics raises $133M Series B for bispecific antibody programs
The startup targets previously undruggable cancer targets and seeks more selective treatments for autoimmune disease.
Read at Biopharmadive โFull coverage ยท 7 outlets
- Biopharmadive ยท lead
- Fierce BiotechT-Therapeutics raises $133M series B for bispecific pipeline with Big Pharma backers in tow
- BioPharma DiveT-Therapeutics reloads with a $133M megaround for bispecifics
- Investors in HealthcareUK: T-Therapeutics closes oversubscribed US$133m Series B to advance TCR bispecific programmes to clinical proof-of-concept
- European Biotechnology MagazineT-Therapeutics raises $133M to bring TCR bispecifics into clinic
- BioXconomyT-Therapeutics nets $133m to push T cell engagers toward the clinic
- YahooT-Therapeutics reloads with a $133M megaround for bispecifics